Skip to main content

Table 1 Inclusion and exclusion criteria for key question 1 and 1a

From: Screening for depression in children and adolescents: a protocol for a systematic review update

  Inclusion Exclusion
Population KQ1: Patients who are up to and including 17 years of age.
KQ1a: Patients who are up to and including 17 years of age selected for screening because they have characteristics that may suggest elevated risk of depression.
For both key questions, caregivers may respond to screening questions on behalf of children. Onset of adolescence will be considered as being age 12.
Characteristics as defined in primary studies
• > 20% of the study sample are adults (18 years and older), have a recent history of depression, have a current diagnosis, or are receiving treatment for depression or other mental disorders (unless results are provided separately from the sample of interest)
• Members of the study sample are seeking services due to symptoms of mental disorders
• Members of the study sample are receiving assessment or care in psychiatric or mental health settings
• Members of the study sample are currently pregnant or have given birth in the past year
Intervention Screening tools that use a single question, a small set of questions, or a screening questionnaire (validated or non-validated) with a pre-defined cut-off score to identify patients who may have depression, but who have not previously reported their symptoms to healthcare providers or who have otherwise not been identified as possibly depressed by healthcare providers.
Patients and/or their guardians have the ability to answer screening tool questions
Screening tools that, in addition to screening, include depression care referral or treatment options not available to patients identified as depressed in the non-screening trial arm
Comparator No depression screening.
• Patients in comparator arms may be administered depression symptom questionnaires for the purpose of baseline or outcome assessments as long as scores are not provided to the patients or healthcare providers prior to start of intervention.
 
Outcomes Critical
1. Symptoms of depression (measured continuously or dichotomously) or diagnosis of MDD (using a validated diagnostic interview)
2. Health-related quality of life (validated tool)
3. Suicidality (suicide ideation, plan, attempt or completion)
4. Social function (e.g., partner, peer, work and family relationships)
5. Impact on lifestyle behavior (e.g., substance abuse)
Important
6. School performance
7. Lost time at work/school
8. False-positive result (i.e., positive screen in absence of depressive disorder), overdiagnosis, or overtreatment
9. Labeling
10. Harms of treatment
 
Setting Primary care or non-mental health clinic settings, such as medical specialist clinics, schools or recreational/community settings, and online settings (e.g., online depression screening), where screening is administered by a health practitioner Studies conducted in mental health, or psychiatric settings. Studies in non-mental health clinic settings where screening is administered by a non-health practitioner.
Study design Randomized controlled trials (RCTs), including cluster-randomized trialsa
If no or only a single RCT is available, then controlled studies without random assignmentb
RCTs where patient eligibility is determined, and patients are enrolled after randomization.
Interrupted times series, single cohort studies, case-control studies, cross-sectional studies, case series, case reports, and other publication types (editorials, commentaries, notes, letter, opinions).
Publication language English or French Languages other than English and French.
Dates of publication January 2017 to present (RCTs)
January 2015 to present (non-randomized controlled studies)
 
  1. aEligible RCTs will need to meet the following criteria: wherein patient eligibility is determined and then patients are enrolled prior to randomization (i.e., to screening or to no screening); similar resources for depression management and treatment must be available both to patients in the screening arm of the trial and to patients in the non-screening arm of the trial who are identified as depressed via other methods (e.g., unaided clinician diagnosis, patient report) [43]
  2. bEligible nonrandomized controlled studies will need to meet the following criteria: Similar resources for depression management and treatment must be available both to patients in the screening arm of the trial and to patients in the non-screening arm of the trial who are identified as depressed via other methods (e.g., unaided clinician diagnosis, patient report) [43]